Eli Lilly (LLY) is a Top-Ranked Growth Stock: Should You Buy?

Company Overview - Eli Lilly and Company, based in Indianapolis, IN, is one of the world's largest pharmaceutical companies with a diversified product profile, including successful new drugs and a reliable pipeline in obesity, diabetes, and Alzheimer's [12]. Investment Potential - Eli Lilly is currently rated 3 (Hold) on the Zacks Rank, with a VGM Score of B, indicating a solid investment potential [12]. - The company is particularly appealing to growth investors, with a Growth Style Score of B, forecasting year-over-year earnings growth of 37.6% for the current fiscal year [13]. - In the last 60 days, five analysts have revised their earnings estimates higher for fiscal 2026, with the Zacks Consensus Estimate increasing by $0.47 to $33.31 per share [13]. - Eli Lilly has an average earnings surprise of +8%, further enhancing its attractiveness to investors [13].